Figure 7.
Brolucizumab q12 and aflibercept q8: total fluid burden—combined intraretinal and subretinal fluid. Reduction in total fluid from baseline with brolucizumab (blue) and aflibercept (red) treatment.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.